Answers are grounded in this paper and cite their sources.
Currently, five medications have been approved by the FDA to treat Alzheimer's disease (AD); Donepezil, which is used at all stages of AD, galantamine, and rivastigmine for mild to moderate stages, and Memantine and a combination of Memantine and donepezil for moderate to severe stages. The ability of these drugs to cross the blood-brain barrier (BBB) determines their exact efficacy. Numerous biomaterials were introduced as a vector for drug agents and increased bioavailability. In this review, we summarized several biomaterials which were used in the treatment of AD.
No takes yet. Share an insight, caveat, or question.
Elham Ramezannezhad (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: